We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Value Investor Highlights: FOXF, BHC and QNST
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 28, 2026 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: https://www.zacks.com/stock/news/2995513/screening-for-hidden-gem-stocks-under-20
Screening for Hidden Gem Stocks Under $20
Welcome to Episode #455 of the Value Investor Podcast.
(0:40) - Finding Affordable Stocks With Strong Performance
(5:15) - Tracey’s Top Picks For Your Radar Right Now
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
Are you tired of paying over $100 for a good value stock? Or even $1000?
The price of a stock doesn’t indicate whether it’s a value, but most mom-and-pop investors, including Tracey, don’t like buying the high-priced stocks. It’s just not as fun to buy one share of a $1500 stock versus 75 shares of a $20 stock for the same $1500.
Screening for Value Stocks Under $20
But are there any top value stocks that are trading for under $20?
Tracey set up a simple screen to find out. It included stocks under $20 which were also Zacks Rank #1 (Strong Buys), the top Zacks Rank. Hopefully, the Zacks #1 Rank should capture analyst bullishness.
For value, Tracey used a price-to-sales (P/S) ratio under 1.0. A P/S ratio of 0.7, for example, means an investor is buying $1.00 of sales for just $0.70. That’s a deal.
She didn’t screen for market cap or any other value fundamentals like low price-to-earnings (P/E) or price-to-book (P/B) ratios. But many of the stocks in the screen had low P/E and P/B ratios anyway.
Fox Factory Holdings Corp. designs and manufactures premium products that deliver championship-level performance for specialty sports and on- and off- road vehicles. In business for about 50 years, it is also a direct supplier of shocks, suspension, and components to leading powered vehicle and bicycle manufacturers. Fox Factory is a small cap company, with a market cap of $793 million.
Earnings have fallen the prior three years but are expected to rise 44% in 2026. Fox Factory is a value stock. Not only does it have a P/S ratio of just 0.5, but it also has a P/E ratio of 12.2.
Fox Factory is trading around $18.40.
Should a specialty products company like Fox Factory be on your short list?
Bausch Health is a global pharmaceutical company headquartered in Quebec, Canada which also owns a controlling interest in Bausch & Lomb, the eye health company. It’s a small cap company with a market cap of $2.2 billion.
In the second quarter of 2026, it saw revenue up 13% to $2.85 billion. It was the highest revenue in three years for the business, excluding Bausch & Lomb.
Earnings are expected to rise 13.6% in 2026. But the shares of Bausch Health have sold off this year, falling 18.4%. That has made it even cheaper.
Bausch Health now trades with a forward P/E of just 1.3. Yes, you read that right. Bausch Health is trading around $5.70 while the Zacks Consensus for 2026 earnings is calling for $4.35.
Should value investors put a pharmaceutical company like Bausch Health on their stocks under $20 list?
QuinStreet is a leader in performance marketplaces and technologies for the financial services and home services industries. It’s a small cap company like the other two, with a market cap of $817 million.
On Aug 6, 2026, QuinStreet reported its fiscal fourth quarter and full year 2026 results. It saw record full-year revenue of $1.3 billion, up 18% year-over-year. The company expects margin expansion in fiscal 2027 and to grow revenue at “strong” double digit rates. Analysts expect earnings to grow 26% in fiscal 2027, after growing earnings by 44.3% in fiscal 2026.
Shares of QuinStreet have plunged 19.5% in the last five days and are down 30.6% in the last month. It now trades around $14.25.
QuinStreet is a value stock with a P/S ratio of 0.7 and a forward P/E of 8.9. A P/E under 10 usually indicates deep value.
Is the recent stock weakness a buying opportunity in QuinStreet?
What Else Should You Know About Value Stocks Under $20?
Tune into this week’s podcast to find out.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
Zacks Value Investor Highlights: FOXF, BHC and QNST
For Immediate Release
Chicago, IL – September 28, 2026 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: https://www.zacks.com/stock/news/2995513/screening-for-hidden-gem-stocks-under-20
Screening for Hidden Gem Stocks Under $20
Welcome to Episode #455 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
Are you tired of paying over $100 for a good value stock? Or even $1000?
The price of a stock doesn’t indicate whether it’s a value, but most mom-and-pop investors, including Tracey, don’t like buying the high-priced stocks. It’s just not as fun to buy one share of a $1500 stock versus 75 shares of a $20 stock for the same $1500.
Screening for Value Stocks Under $20
But are there any top value stocks that are trading for under $20?
Tracey set up a simple screen to find out. It included stocks under $20 which were also Zacks Rank #1 (Strong Buys), the top Zacks Rank. Hopefully, the Zacks #1 Rank should capture analyst bullishness.
For value, Tracey used a price-to-sales (P/S) ratio under 1.0. A P/S ratio of 0.7, for example, means an investor is buying $1.00 of sales for just $0.70. That’s a deal.
She didn’t screen for market cap or any other value fundamentals like low price-to-earnings (P/E) or price-to-book (P/B) ratios. But many of the stocks in the screen had low P/E and P/B ratios anyway.
3 Hidden Gem Stocks Under $20
1. Fox Factory Holdings Corp. (FOXF - Free Report)
Fox Factory Holdings Corp. designs and manufactures premium products that deliver championship-level performance for specialty sports and on- and off- road vehicles. In business for about 50 years, it is also a direct supplier of shocks, suspension, and components to leading powered vehicle and bicycle manufacturers. Fox Factory is a small cap company, with a market cap of $793 million.
Earnings have fallen the prior three years but are expected to rise 44% in 2026. Fox Factory is a value stock. Not only does it have a P/S ratio of just 0.5, but it also has a P/E ratio of 12.2.
Fox Factory is trading around $18.40.
Should a specialty products company like Fox Factory be on your short list?
2. Bausch Health Companies Inc. (BHC - Free Report)
Bausch Health is a global pharmaceutical company headquartered in Quebec, Canada which also owns a controlling interest in Bausch & Lomb, the eye health company. It’s a small cap company with a market cap of $2.2 billion.
In the second quarter of 2026, it saw revenue up 13% to $2.85 billion. It was the highest revenue in three years for the business, excluding Bausch & Lomb.
Earnings are expected to rise 13.6% in 2026. But the shares of Bausch Health have sold off this year, falling 18.4%. That has made it even cheaper.
Bausch Health now trades with a forward P/E of just 1.3. Yes, you read that right. Bausch Health is trading around $5.70 while the Zacks Consensus for 2026 earnings is calling for $4.35.
Should value investors put a pharmaceutical company like Bausch Health on their stocks under $20 list?
3. QuinStreet, Inc. (QNST - Free Report)
QuinStreet is a leader in performance marketplaces and technologies for the financial services and home services industries. It’s a small cap company like the other two, with a market cap of $817 million.
On Aug 6, 2026, QuinStreet reported its fiscal fourth quarter and full year 2026 results. It saw record full-year revenue of $1.3 billion, up 18% year-over-year. The company expects margin expansion in fiscal 2027 and to grow revenue at “strong” double digit rates. Analysts expect earnings to grow 26% in fiscal 2027, after growing earnings by 44.3% in fiscal 2026.
Shares of QuinStreet have plunged 19.5% in the last five days and are down 30.6% in the last month. It now trades around $14.25.
QuinStreet is a value stock with a P/S ratio of 0.7 and a forward P/E of 8.9. A P/E under 10 usually indicates deep value.
Is the recent stock weakness a buying opportunity in QuinStreet?
What Else Should You Know About Value Stocks Under $20?
Tune into this week’s podcast to find out.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec and she also hosts the Zacks Market Edge Podcast on iTunes.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.